Capstan Therapeutics, Inc. announced that it has received $101.999962 million in funding from a group of investors

On September 14, 2022, Capstan Therapeutics, Inc. closed the transaction. The company received $101,999,961.8132 in the transaction led by new investor, Pfizer Venture Investments LLC. The transaction also included participation from new investors, Leaps by Bayer, Eli Lilly and Company, Bristol-Myers Squibb Company, Polaris Partners LLC, Alexandria Venture Investments, LLC and all existing investors including, Novartis Venture Funds, OrbiMed Advisors LLC, RA Capital Management, L.P. and Vida Ventures Advisors, LLC.

The company has raised $165,000,000 in funding till date.